Abstract
Background:
Sex-specific responsos to antihypertensive drugs are not very well understood.
Objective:
To investigate sex-related differences in blood pressure response to antihypertensive drugs in a community-based prospective clinical trial.
Methods:
We recruited 3535 untreated hypertensive patients (2326 women), aged 40–75 years, from 7 rural communities in China. Subjects were randomized to 1 of 4 drug groups: atenolol, hydrochlorothiazide (HCTZ), captopril, or sustained-released nifedipine; duration of the study was 8 weeks. Mean blood pressure reduction, blood pressure control rates, and frequency of adverse events were compared between men and women.
Results:
Women had a better response to HCTZ in relation to diastolic blood pressure (1.8 mm Hg lower) than did men (p <0.05) and were 57% more likely to reach the control goal of diastolic blood pressure than were men (p <0.05). In the atenolol group, mean systolic blood pressure decreased 3.9 mm Hg more in women than in men (p <0.05), and women were 65% more likely to reach the control goal of systolic blood pressure and 57% more likely to reach the control goal of diastolic blood pressure than were men (p <0.05). Significant sex-related differences were also found in drug-related adverse events in the nifedipine group (15.8% in women vs 9.8% in men; p = 0.017) and in the captopril group (14.3% in women vs 8.4% in men; p = 0.005), but no differences were seen with HCTZ or atenolol.
Conclusions:
Women have better blood pressure responses to HCTZ and atenolol and experience more adverse effects with sustained-release nifedipine and captopril than do men, indicating that sex should be taken into account when selecting antihypertensive drugs.
Get full access to this article
View all access options for this article.